165 related articles for article (PubMed ID: 16646004)
1. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
Stone JH; Holbrook JT; Marriott MA; Tibbs AK; Sejismundo LP; Min YI; Specks U; Merkel PA; Spiera R; Davis JC; St Clair EW; McCune WJ; Ytterberg SR; Allen NB; Hoffman GS;
Arthritis Rheum; 2006 May; 54(5):1608-18. PubMed ID: 16646004
[TBL] [Abstract][Full Text] [Related]
2. Etanercept plus standard therapy for Wegener's granulomatosis.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
N Engl J Med; 2005 Jan; 352(4):351-61. PubMed ID: 15673801
[TBL] [Abstract][Full Text] [Related]
3. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.
Stone JH;
Arthritis Rheum; 2003 Aug; 48(8):2299-309. PubMed ID: 12905485
[TBL] [Abstract][Full Text] [Related]
4. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.
Stone JH; Uhlfelder ML; Hellmann DB; Crook S; Bedocs NM; Hoffman GS
Arthritis Rheum; 2001 May; 44(5):1149-54. PubMed ID: 11352248
[TBL] [Abstract][Full Text] [Related]
5. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
Seo P; Min YI; Holbrook JT; Hoffman GS; Merkel PA; Spiera R; Davis JC; Ytterberg SR; St Clair EW; McCune WJ; Specks U; Allen NB; Luqmani RA; Stone JH;
Arthritis Rheum; 2005 Jul; 52(7):2168-78. PubMed ID: 15986348
[TBL] [Abstract][Full Text] [Related]
6. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
Wung PK; Holbrook JT; Hoffman GS; Tibbs AK; Specks U; Min YI; Merkel PA; Spiera R; Davis JC; St Clair EW; McCune J; Ytterberg SR; Allen NB; Stone JH;
Am J Med; 2005 Dec; 118(12):1416. PubMed ID: 16378799
[TBL] [Abstract][Full Text] [Related]
7. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.
Silva F; Seo P; Schroeder DR; Stone JH; Merkel PA; Hoffman GS; Spiera R; Sebastian JK; Davis JC; St Clair EW; Allen NB; McCune WJ; Ytterberg SR; Specks U;
Arthritis Rheum; 2011 Aug; 63(8):2495-503. PubMed ID: 21484770
[TBL] [Abstract][Full Text] [Related]
8. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
Jatoi A; Dakhil SR; Nguyen PL; Sloan JA; Kugler JW; Rowland KM; Soori GS; Wender DB; Fitch TR; Novotny PJ; Loprinzi CL
Cancer; 2007 Sep; 110(6):1396-403. PubMed ID: 17674351
[TBL] [Abstract][Full Text] [Related]
10. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
Mukhtyar C; Luqmani R
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv31-6. PubMed ID: 16239383
[TBL] [Abstract][Full Text] [Related]
11. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.
Martínez-Taboada VM; Rodríguez-Valverde V; Carreño L; López-Longo J; Figueroa M; Belzunegui J; Mola EM; Bonilla G
Ann Rheum Dis; 2008 May; 67(5):625-30. PubMed ID: 18086726
[TBL] [Abstract][Full Text] [Related]
12. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.
Metzler C; Miehle N; Manger K; Iking-Konert C; de Groot K; Hellmich B; Gross WL; Reinhold-Keller E;
Rheumatology (Oxford); 2007 Jul; 46(7):1087-91. PubMed ID: 17519271
[TBL] [Abstract][Full Text] [Related]
13. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.
Koldingsnes W; Nossent JC
J Rheumatol; 2003 Jan; 30(1):80-8. PubMed ID: 12508394
[TBL] [Abstract][Full Text] [Related]
14. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s.
Abdou NI; Kullman GJ; Hoffman GS; Sharp GC; Specks U; McDonald T; Garrity J; Goeken JA; Allen NB
J Rheumatol; 2002 Feb; 29(2):309-16. PubMed ID: 11838848
[TBL] [Abstract][Full Text] [Related]
15. Design of the Wegener's Granulomatosis Etanercept Trial (WGET).
WGET Research Group
Control Clin Trials; 2002 Aug; 23(4):450-68. PubMed ID: 12161090
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of remission with leflunomide in Wegener's granulomatosis.
Metzler C; Fink C; Lamprecht P; Gross WL; Reinhold-Keller E
Rheumatology (Oxford); 2004 Mar; 43(3):315-20. PubMed ID: 14963200
[TBL] [Abstract][Full Text] [Related]
17. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.
Langford CA; Talar-Williams C; Barron KS; Sneller MC
Arthritis Rheum; 1999 Dec; 42(12):2666-73. PubMed ID: 10616016
[TBL] [Abstract][Full Text] [Related]
18. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
Knight A; Askling J; Granath F; Sparen P; Ekbom A
Ann Rheum Dis; 2004 Oct; 63(10):1307-11. PubMed ID: 15130900
[TBL] [Abstract][Full Text] [Related]
19. A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group.
Lamprecht P; Gross WL
Arthritis Rheum; 2004 Jan; 50(1):334-5; author reply 335-6. PubMed ID: 14730635
[No Abstract] [Full Text] [Related]
20. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
